Successful Interim Analysis in Phase 3 Heart Failure Trial
Filed with ASX · · 3 pages · English
Story so far
Earlier from Mesoblast
- Mesoblast Receives A$3.7m From Aus Govt For R&D
- FDA Clears Heart Disease Trial At Boston Childrens Hospital
- Process Initiated For CHF P3 Interim Analysis
- Mesoblast Raises US$40 Million
- Durable Three Year Outcomes in Disc Disease
Later from Mesoblast
- Third Quarter Financial Results On Form 6-K
- MSB Provides Q3 Operational Highlights and Financial Results
- Mesoblast RA Results Presented At EULAR Congress
- Positive Results of MSB Therapy in Osteoarthritis Published
- Potential For Accelerated Market Entry In Advanced CHF
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast